A phase 3 randomised non-inferiority trial to evaluate the most effective way to use imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Trial Profile

A phase 3 randomised non-inferiority trial to evaluate the most effective way to use imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Imatinib (Primary) ; Nilotinib (Primary) ; Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-3
  • Most Recent Events

    • 03 Aug 2017 This trial has been completed in UK , according to European Clinical Trials Database.
    • 26 Sep 2016 Status changed from recruiting to discontinued.
    • 28 Dec 2015 Planned End Date changed from 1 Sep 2023 to 29 Feb 2020 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top